Jacob Sartorius is one of Gen Z’s rising stars. The pop singer amassed a massive following when he started posting lip-syncing videos on Vine and Musical.ly in 2014 at just 11 years old. Now he’s a ...
Investing.com -- Sartorius Stedim Biotech SA (EPA:STDM) reported first-quarter net profit of €88 million on Thursday, up 3% ...
Hosted on MSN
Your Sartorius is the Long Muscle in Your Thigh and it Causes Pain and Wants to Stretch
When hip and knee pain strike, many runners suspect it’s their iliotibial (IT) band. While this thick band of tissue is a common culprit for hip and knee pain, there may be another muscle at play: the ...
Sartorius Stedim Biotech, a supplier of equipment and services to the biopharmaceutical industry, reported higher ...
Sartorius AG (SSSGY) reports a 7.5% increase in sales revenue, driven by Bioprocess Solutions and innovative product launches, while navigating geopolitical and macroeconomic challenges.
"It's an ongoing journey and I'm finding my answers along the way," Sartorius tells PEOPLE Jacob Sartorius has always known he was adopted. "I was adopted right around birth," Sartorius, 19, tells ...
Investing.com -- Sartorius Stedim Biotech SA (EPA:STDM) reported first-quarter net profit of €88 million on Thursday, up 3% ...
During May and June 2023 several sub-sales and distribution agreements were signed between Sartorius and BICO companies CELLINK, Advanced BioMatrix (ABM) and Dispendix. In addition, R&D project ...
Sartorius announced the 2.4 billion euro acquisition of Polyplus. Polyplus is producing transfection reagents and generates 100 million euros in revenues. The acquisition appears to be very expensive ...
Sartorius will face uncertainty. In Nov 2025, its CEO will leave the company, and in 2028, the community of heirs will take the full right of their common share. The company has high debt levels. In ...
March 31 (Reuters) - Sartorius (SATG.DE), opens new tab will acquire French lab technology company Polyplus for 2.4 billion euros ($2.62 billion) from private investors to strengthen its activities ...
Sartorius Stedim Biotech agreed to buy Polyplus, a maker of components for cell and gene therapies, for about €2.4 billion ($2.6 billion) from a group of private investors. The deal would bolster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results